Di Minno, G., & Ravasio, R. (2021). Cost-effectiveness analysis of caplacizumab in the new standard of care for immune Thrombotic Thrombocytopenic Purpura in Italy. Global and Regional Health Technology Assessment, 8(1), 43–52. https://doi.org/10.33393/grhta.2021.2191